Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with clinical diagnosis of moderate to severe facial rosacea as determined by:~   * At least 8 but no more than 50 total papules and/or pustules (inflammatory lesions)~  * Presence of moderate to severe erythema~  * Presence of telangiectasia.~  * An Overall Rosacea Severity score ≥2.5~2. Patient is male or female over 18 years of age.~3. No known medical conditions that, in the Investigator's opinion could interfere with study participation~4. Patient is willing and able to comply with all requirement of the protocol~5. Patient is willing and able to give written informed consent prior to participation in the study~Exclusion Criteria:~1. Presence of skin diseases at or near the investigational area~2. Immunosuppressed state or other serious systemic disease~3. Signs and/or symptoms of systemic infection~4. Concomitant medication:~   * Use of oral and/or topical antibiotic treatment within 14 days prior to study entry.~  * Use of any topical anti-rosacea agent except antibiotics within 14 days prior to study entry.~  * Use of cyproterone acetate, CPA-containing contraceptives (e.g. Diane) or other corticosteroids (during the last 3 months);~  * Use of retinoids (during the last 4 weeks)~5. Use of artificial sun bath or having a sun holiday during the last 2 weeks~6. Alcohol or drug abuse, according to assessment by the investigator~7. Known or suspected hypersensitivity to Minocycline or any of the excipients in the Study Medication~8. Use of another investigational drug within 30 days prior to entry into this study~9. Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topical Minocycline Foam FXFM244 Placebo (Type: PLACEBO_COMPARATOR): Minocycline Foam FXFM244 Placebo
- Topical Minocycline Foam FXFM244, 1% (Type: EXPERIMENTAL): Minocycline Foam FXFM244, 1%
- Topical Minocycline Foam FXFM244, 4% (Type: EXPERIMENTAL): Minocycline Foam FXFM244, 4%

Based on this trial design, predict the completion outcome and termination type (if applicable).